BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21549885)

  • 1. [Kidney and iodinated and gadolinium-based contrast agents].
    Clément O; Faye N; Fournier L; Siauve N; Frija G
    J Radiol; 2011 Apr; 92(4):291-8. PubMed ID: 21549885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal toxicity of contrast agents in oncologic patients].
    Amet S; Deray G
    Bull Cancer; 2012 Mar; 99(3):295-307. PubMed ID: 22082610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity of contrast media: an update.
    ten Dam MA; Wetzels JF
    Neth J Med; 2008 Nov; 66(10):416-22. PubMed ID: 19011267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
    Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
    JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
    Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
    Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nephrogenic systemic fibrosis or kidney failure--how great is the risk?].
    Rofo; 2010 Feb; 182(2):114-5. PubMed ID: 20120045
    [No Abstract]   [Full Text] [Related]  

  • 9. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
    Penfield JG; Reilly RF
    Semin Dial; 2011; 24(5):480-6. PubMed ID: 21913988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of gadolinium for arterial interventions.
    Sambol EB; Van der Meer JG; Graham A; Goldstein LJ; Karwowski JK; Dayal R; Derubertis B; Kent KC
    Ann Vasc Surg; 2011 Apr; 25(3):366-76. PubMed ID: 21288688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E; Semelka RC; Cakit C
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents.
    Langer RD; Lorke DE; Neidl van Gorkom KF; Petroianu G; Azimullah S; Nurulain SM; Singh S; Fuchsjäger M
    Eur J Radiol; 2012 Oct; 81(10):2562-7. PubMed ID: 22304979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
    Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
    Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for NSF: a literature review.
    Prince MR; Zhang HL; Roditi GH; Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1298-308. PubMed ID: 19937930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of nephrogenic systemic fibrosis at two large medical centers.
    Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
    Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
    Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.